ArQule Announces Initiation of Two Phase 2 Trials with c-Met Inhibitor, ARQ 197.
Business Wire › October 31, 2007
Linked as:
Extract
ArQule Announces Initiation of Two Phase 2 Trials with c-Met Inhibitor, ARQ 197.
Trials target MiT tumors and pancreatic cancer
WOBURN, Mass. -- ArQule, Inc. (NASDAQ: ARQL) today announced the initiation of two Phase 2 trials with ARQ 197, an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with MiT (Microphthalmia Transcription Factor) tumors and pancreatic cancer. MiT tumors include clear cell sarcoma (CCS), alveolar soft part sarcoma (ASPS) and translocation-a...See the full content of this document
Sponsored links
